In the case of stimulating O-GlcNAcylation of proteins, inexpensive inhibitors, such as NButGT, have never been tested in humans, and those that have entered human clinical trials are still in phase 2 and for indications in chronic pathology that may have drawbacks over a long period of treatment [18]
However, our rigorous matching procedures with the intention to achieve a greater level of between-group comparability on a wide range of baseline patient characteristics (i.e., prior GLA exposure history, comorbidities, diabetes severity, and co-medications) and the regression analyses with adjustment for imbalanced baseline characteristics may have minimized this concern
SGLT2GLP-1 20234 GIP/GLP-1 GIP/GLP11 GLP-1 GLP-1GIPGIP/GLP-1 GLP-1 GLP-1-1GLP-1 GLP-1GLP-1 GIP GIPGLP-1 GIP GLP-1GIP HbA1c SRPUSS J-mono2 HbA15mg/10mg/15mg10.75 2636 HbA1c 5mg-2.4 10mg-2.6 15mg-2.8 0.75mg-1.3 HbA1c 52HbA1c7.0 5mg94% 10mg97% 15mg99% 0.75mg67% 9HbA1c7.0 5mg-5.8kg 10mg-8.5kg 15mg-10.7kg 0.75mg-0.5kg 15mg-10.7kg 16~18% 12~20%14~18%13~22%9~17%5~12% 8%11%4%11%1% HbA1c 1 0.25mg40.5mg 40.25mg 2.5mg1924/ 5mg3848/ 7.5mg5772/ 10mg7696/ 15mg11544/ 2807/ 2mg11008/ 432300~14000 2 Kadowaki T, Chin R, Ozeki A, et al
However, many need more often twice or thrice for better metabolism and energy
